Glioblastoma Market Snapshot: Two Approvals In 2024 And A Rich Pipeline

Glioblastoma carries a grim prognosis. The biopharma industry is trying to improve patient outcomes, with 120 drugs in the pipeline and two anticipated approvals this year.

Soft and blurry image:Medical image MRI Brain showing There is diameter cystic mass or tumor at Left frontal lobe Glioblastoma at Lt frontal lobe with metastasis, brain metastases.
Biopharma Investments Offer Hope For Glioblastoma Patients • Source: Shutterstock

Patients with glioblastoma can expect to live a median eight months after diagnosis, but two anticipated launches in 2024 and a rich development pipeline could improve that bleak clinical outlook.

“There’s never been so much cause for hope. The standard of care hasn’t changed for 25 years,” Will Jones, chief...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Market Intelligence

More from In Vivo